Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1826)	11/8/1998 5:02:00 AM
From: trofala	Read Replies (1) \| Respond to of 1894

Sigmond, If Accumed is going to "CELL" the cyto business and keep the micro business then what happens with this deal: ...Sept 8 (Reuters) - AccuMed International Inc., an advanced diagnostics and information solutions company, said Tuesday it reached an agreement with its former chairman and chief executive Peter Gombrich. Gombrich, currently chairman of InPath LLC, will acquire from AccuMed a license to a patent application and technology owned by AccuMed in point-of-care systems. The deal involves Accumed receiving from Gombrich a one-time licensing fee of $500,000, seven percent royalties of InPath's gross revenues with minimum annual financial payments for five years and an equity position in InPath Does that go with the deal? And what happens with Onocentrics? (Does pin the tail on the donkey come to mind?) For the record I prefer if they kept the micro division. Ray